We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
18 Mar 2021 - 21 Mar 2021
13 Apr 2021 - 16 Apr 2021

RDW Levels Associated with Adverse Outcomes in COVID-19 Patients

By LabMedica International staff writers
Posted on 04 Feb 2021
Print article
Image: Human erythrocytes showing variation in red cell distribution width (RDW), known as anisocytosis, higher levels may predict mortality in COVID-19 patients (Photo courtesy of Dr. Graham Beards)
Image: Human erythrocytes showing variation in red cell distribution width (RDW), known as anisocytosis, higher levels may predict mortality in COVID-19 patients (Photo courtesy of Dr. Graham Beards)
The red cell distribution width (RDW) blood test measures the amount of red blood cell variation in volume and size. RDW is not used as an isolated parameter when interpreting a complete blood count (CBC); instead, it provides shades of meaning in the context of the hemoglobin (Hgb) and mean corpuscular value (MCV).

Increasing scientific evidence has shown that abnormalities in routine laboratory tests, particularly hematological tests, have the potential to indicate, in a quick, practical and economical way, the need for specific laboratory tests for the diagnosis of SARS-CoV-2 infection, besides assisting in the prognosis of the disease and in the optimization of its clinical monitoring.

Medical Scientists from several institutions including the Baim Institute for Clinical Research (Boston, MA, USA) performed a comprehensive literature search from inception to September 2020 to harvest original studies reporting RDW on admission and clinical outcomes among patients hospitalized with COVID-19. The study endpoint was adverse clinical outcomes, defined as the composite of mortality or severe COVID-19. A total of 14,866 patients from 10 studies were included in the meta-analysis. The mean age ranged from 38 to 77 years while the proportion of males ranged from 42.4% to 69.2%.

The investigators reported that the meta-analysis found that higher levels of RDW were associated with adverse outcomes in COVID-19 patients (mean differences, 0.72; 95% confidence interval [CI], 0.47-0.97; I2, 89.51%). Further, results of the subgroup analysis showed that deceased patients had higher levels of RDW compared to survived patients (mean differences, 0.93; 95% CI, 0.63-1.23; I2, 85.58%). Similarly, severely ill COVID-19 patients had higher levels of RDW, as opposed to patients classified to have milder symptoms (mean differences, 0.61; 95% CI, 0.28-0.94; I2, 82.18%).

Jane J Lee, PhD, the first author of the study, said, “Emerging evidence has underscored the potential usefulness of RDW measurement in predicting the mortality and disease severity of COVID-19. As RDW is widely available and included as a routine parameter of complete blood count, this simple laboratory test can be particularly useful in the context of COVID-19 pandemic, where identifying high-risk patients and facilitating timely intervention with limited resources are critical.”

The authors noted that the exact pathophysiology behind the association between increased RDW and adverse outcomes has yet to be elucidated. Numerous reports have suggested that COVID-19 infection was associated with an increase in the release and production of white blood cell counts and platelets from the bone marrow. The stimulation to the bone marrow may also impact the red blood cell (RBC) kinetics, resulting in a wider range of RBC size and subsequently elevated RDW levels. The study was published on January 15, 2021 in the Journal of Medical Virology.

Related Links:
Baim Institute for Clinical Research

Gold Supplier
POC Analyzer
Epithod 616
Respiratory SARS-CoV-2 Panel
QIAstat-Dx Respiratory SARS-CoV-2 Panel
Gold Supplier
SARS-CoV-2 Assay
SARS-CoV-2 Nucleic Acid Detection Kit
SARS-CoV-2 Nucleic Acid Detection Kit

Print article


Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more


view channel

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.